Here is something to get excited about... may be an oppps moment for UCLA staff for telling a bit too much:
http://www.emaxhealth.com/91/23327.html
From the article:
"Recent announced results from the Phase II study showed that bapineuzumab resulted in improvements on memory tests in patients who received the therapy, compared to those who received a placebo, and also helped reduce brain shrinkage (compared to those receiving placebo), a common symptom of the disease."
Now we know how well AAB-001 works!